Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Cited by (1,001)

Items 101–200 of 1,001

1. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant
   Cai He, Jingyun Yang, Weiqi Hong, Zimin Chen, Dandan Peng, Lei Hong, Aqu Alu, Xuemei He, Zhenfei Bi, Xiaohua Jiang et al. · 2022 · Nature Communications
2. Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection
   Rachel M. Gittelman, Enrico Lavezzo, Thomas M. Snyder, Harus Jabran Zahid, Cara L. Carty, Rebecca Elyanow, Sudeb C. Dalai, Ilan Richard Kirsch, Lance Baldo, Laura Manuto et al. · 2022 · JCI Insight
3. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
   Subhash Thuluva, Vikram M. Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Guruprasad R. Medigeshi, Janmejay Singh et al. · 2022 · EBioMedicine
4. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
   Dapeng Li, David R. Martinez, Alexandra Schäfer, Haiyan Chen, Maggie Barr, Laura L. Sutherland, Esther Lee, Robert Parks, Dieter Mielke, Whitney Edwards et al. · 2022 · Nature Communications
5. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
   Alexis Maillard, Rabah Redjoul, Marion Klémencie, Hélène Labussière Wallet, Amandine Le Bourgeois, Maud D’Aveni, Anne Huynh, Ana Berceanu, Tony Marchand, Sylvain Chantepie et al. · 2021 · Blood
6. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
   Spyros Chalkias, Jordan L. Whatley, Frank S. Eder, Brandon J. Essink, Shishir K. Khetan, Paul Bradley, Adam B. Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen et al. · 2023 · Nature Medicine
7. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung
   Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, Danielle A. Wagner, Shayne F. Andrew, John-Paul M. Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T. Nurmukhambetova et al. · 2021 · Cell
8. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
   Lin‐Lei Chen, Gilbert T. Chua, Lu Lu, Brian Pui-Chun Chan, Joshua Sung Chih Wong, Calvin Chit Kwong Chow, Tak-Ching Yu, Agnes Sze Yin Leung, Shu-Yan Lam, Tak-Wai Wong et al. · 2022 · Emerging Microbes & Infections
9. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
   Cyril Planchais, Ignacio Fernández, Timothée Bruel, Guilherme Dias de Melo, Matthieu Prot, Maxime Beretta, Pablo Guardado‐Calvo, Jérémy Dufloo, Luis Manuel Molinos-Albert, Marija Backović et al. · 2022 · The Journal of Experimental Medicine
10. Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong
    Chen, Lin-Lei, Abdullah, Syed Muhammad Umer, Chan, Wan-Mui, Chan, Brian Pui-Chun, Ip, Jonathan Daniel, Chu, Allen Wing-Ho, Lu, Lu, Zhang, Xiaojuan, Zhao, Yan, Chuang, Vivien Wai-Man et al. · 2022 · Nature Communications
11. WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
    Feng Zhu, Thomas Althaus, Chee Wah Tan, Alizée Costantini, Wan Ni Chia, Nguyen Van Vinh Chau, Le Van Tan, Giada Mattiuzzo, Nicola J. Rose, Eric J. Voiglio et al. · 2021 · The Lancet Microbe
12. Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
    Deepta Bhattacharya · 2022 · Immunity
13. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
    Wei Wang, Sabrina Lusvarghi, Rahul Subramanian, Nusrat J Epsi, Richard Wang, Emilie Goguet, Anthony C Fries, Fernando Echegaray, Russell A. Vassell, Si’Ana A. Coggins et al. · 2022 · Cell Host & Microbe
14. Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection
    Wang, Wei, Lusvarghi, Sabrina, Subramanian, Rahul, Epsi, Nusrat J., Wang, Richard, Goguet, Emilie, Fries, Anthony C, Echegaray, Fernando, Vassell, Russell, Coggins, Si’Ana et al. · 2022
15. Resolving adjuvant mode of action to enhance vaccine efficacy
    Joanna L. Turley, Ed C. Lavelle · 2022 · Current Opinion in Immunology
16. From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics
    Renata G. F. Alvim, Túlio M. Lima, Danielle A. S. Rodrigues, Federico Francisco Marsili, Vicente B. T. Bozza, Luiza M. Higa, Fábio Luís Lima Monteiro, Daniel Paiva Barros de Abreu, Isabela C. Leitão, Renato Sampaio Carvalho et al. · 2022 · Biochemical Engineering Journal
17. Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines
    Spyros Chalkias, Nichole McGhee, Jordan L. Whatley, Brandon J. Essink, Adam B. Brosz, Joanne E. Tomassini, Bethany Girard, Kaichun Wu, Darin K. Edwards, Arshan Nasir et al. · 2023 · medRxiv
18. Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory
    Kathleen M. Wragg, Wen Shi Lee, Marios Koutsakos, Hyon‐Xhi Tan, Thakshila H. Amarasena, Arnold Reynaldi, Grace Gare, Penny Konstandopoulos, Kirsty R. Field, Robyn Esterbauer et al. · 2022 · Nature Immunology
19. Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review
    Nanny Natalia Mulyani Soetedjo, Maria Riastuti Iryaningrum, Sherly Lawrensia, Hikmat Permana · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
20. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
    Jaime S. Rosa Duque, Xiwei Wang, Daniel Leung, Samuel M. S. Cheng, Carolyn A. Cohen, Xiaofeng Mu, Asmaa Hachim, Yanmei Zhang, Sau Man Chan, Sara Chaothai et al. · 2022 · Nature Communications
21. The role of vaccines in the COVID-19 pandemic: what have we learned?
    Florian Krammer · 2023 · Seminars in Immunopathology
22. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
    Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, Josue Marquez, Dillon R. Flebbe, Anna Mychalowych, Evan Lamb, Meredith E. Davis-Gardner, Matthew R. Burnett, Leonid Serebryannyy et al. · 2024 · Nature Immunology
23. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
    Wanting He, Rami Ghassan Musharrafieh, Ge Song, Katharina Dueker, Longping V. Tse, David R. Martinez, Alexandra Schäfer, Sean Callaghan, Peter Yong, Nathan Beutler et al. · 2022 · Nature Immunology
24. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
    Annika Fendler, Scott T.C. Shepherd, Lewis Au, Katalin Andrea Wilkinson, Mary Wu, Andreas Michael Schmitt, Zayd Tippu, Sheima Farag, Aljosja Rogiers, Ruth Harvey et al. · 2021 · Cancer Cell
25. mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
    Laura Matarazzo, Paulo J. G. Bettencourt · 2023 · Frontiers in Immunology
26. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
    Angela Ramon Branche, Nadine Rouphael, David Joseph Diemert, Ann Regina Falsey, Cecilia Losada, Lindsey Robert Baden, Sharon E. Frey, Jennifer A. Whitaker, Susan J. Little, Evan J. Anderson et al. · 2023 · Nature Medicine
27. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
    Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2022 · Nature Computational Science
28. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants
    Marios Koutsakos, Wen Shi Lee, Arnold Reynaldi, Hyon‐Xhi Tan, Grace Gare, Paul M. Kinsella, Kwee Chin Liew, George Taiaroa, Deborah Anne Williamson, Helen E. Kent et al. · 2022 · Immunity
29. Monoclonal antibody levels and protection from COVID-19
    Eva Stadler, Martin T. Burgess, Timothy E. Schlub, Shanchita Rahnuma Khan, Khai Li Chai, Zoe McQuilten, Erica M. Wood, Mark Niccolo Polizzotto, Stephen John Kent, Deborah Cromer et al. · 2023 · Nature Communications
30. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
    Nita Patel, Jessica F. Trost, Mimi Guebre‐Xabier, Haixia Zhou, Jim Norton, Desheng Jiang, Zhaohui Cai, Mingzhu Zhu, Anthony M. Marchese, Ann M. Greene et al. · 2023 · Scientific Reports
31. mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
    Rishi R. Goel, Mark M. Painter, Sokratis A. Apostolidis, Divij Mathew, Wenzhao Meng, Aaron M. Rosenfeld, Kendall A. Lundgreen, Arnold Reynaldi, David S. Khoury, Ajinkya Pattekar et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
32. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents
    David H. Canaday, Oladayo Ayobami Oyebanji, Elizabeth M. White, Debbie Keresztesy, Michael Payne, Dennis J. Wilk, Lenore L. Carias, Htin Aung, Kerri St. Denis, Maegan L. Sheehan et al. · 2022 · EBioMedicine
33. Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS‐CoV ‐2 infection*
    Salma Sheikh‐Mohamed, Erin C. Sanders, Jennifer L. Gommerman, Michal Caspi Tal · 2022 · Immunological Reviews
34. Vaccination and immunotherapies in neuroimmunological diseases
    Alexander Winkelmann, Micha Loebermann, Michael Harry Barnett, Hans‐Peter Hartung, Uwe Klaus Zettl · 2022 · Nature Reviews Neurology
35. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
    Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Chaisith Sivakorn, Piengthong Narakorn, Somchaiya Surichan, Sumalee Prangpratanporn, Suttida Puksuriwong et al. · 2022 · EClinicalMedicine
36. Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19
    Jennifer L. Alejo, Jonathan Mitchell, Amy Y. Chang, Teresa Po‐Yu Chiang, Allan B. Massie, Dorry Lidor Segev, Martin A. Makary · 2022 · JAMA
37. Immunogenicity and Safety of Standard and Third‐Dose SARS – CoV ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
    Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung The Tran, Joseph Sexton, Sella Aarrestad Provan, Siri Mjaaland, David John Warren, Tore Kristian Kvien, Gunnveig Grødeland et al. · 2022 · Arthritis & Rheumatology
38. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines
    Spyros Chalkias, Nichole McGhee, Jordan L Whatley, Brandon J. Essink, Adam B. Brosz, Joanne E. Tomassini, Bethany Girard, Darin K. Edwards, Kai Wu, Arshan Nasir et al. · 2024 · The Journal of Infectious Diseases
39. Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
    Lassaunière, Ria, Polacek, Charlotta, Frische, Anders, Boding, Lasse, Sækmose, Susanne Gjørup, Rasmussen, Morten, Fomsgaard, Anders · 2022 · JAMA Network Open
40. Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines
    Nusrat J Epsi, Stephanie A Richard, David A Lindholm, Katrin Mende, Anuradha Ganesan, Nikhil Huprikar, Tahaniyat Lalani, Anthony C Fries, Ryan C. Maves, Rhonda E Colombo et al. · 2022 · Clinical Infectious Diseases
41. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
    Laura Pérez‐Alós, Cecilie Bo Hansen, José Juan Almagro Armenteros, Johannes Roth Madsen, Line Dam Heftdal, Rasmus Bo Hasselbalch, Mia Marie Pries‐Heje, Rafael Bayarri‐Olmos, Ida Jarlhelt, Sebastian Rask Hamm et al. · 2023 · Nature Communications
42. Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
    Lisa Loksø Dietz, Anna Karina Juhl, Ole Schmeltz Søgaard, Joanne Reekie, Henrik Nielsen, Işık Somuncu Johansen, Thomas Benfield, Lothar Wiese, Nina Breinholt Stærke, Tomas Østergaard Jensen et al. · 2023 · Communications Medicine
43. Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination
    David H. Canaday, Oladayo Ayobami Oyebanji, Debbie Keresztesy, Michael Payne, Dennis J. Wilk, Lenore L. Carias, Htin Aung, Kerri St. Denis, Evan Christopher Lam, Christopher F. Rowley et al. · 2021 · Clinical Infectious Diseases
44. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
    Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie · 2023 · Frontiers in Immunology
45. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases
    Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N. Albach, Jens Klotsche, Veronika Scholz, Lara Maria Jeworowski, Tatjana Schwarz, Alexander ten Hagen, Jan Zernicke, Victor M. Corman et al. · 2022 · Annals of the Rheumatic Diseases
46. An antibody from single human V H -rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion
    Sai Luo, Jun Zhang, Alex J.B. Kreutzberger, Amanda Eaton, Robert J. Edwards, Changbin Jing, Hai‐Qiang Dai, Gregory D. Sempowski, Kenneth D. Cronin, Robert Parks et al. · 2022 · Science Immunology
47. Intelligent Biomaterialomics: Molecular Design, Manufacturing, and Biomedical Applications
    Yu Yi, Hong‐Wei An, Hao Wang · 2023 · Advanced Materials
48. Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection
    Anna Wald · 2022 · JAMA
49. Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
    Jan‐Stephan Sanders, A. Lianne Messchendorp, Rory D. de Vries, Carla C. Baan, Debbie van Baarle, Rob S. van Binnendijk, Dimitri Adriaan Diavatopoulos, Daryl Geers, Katharina S. Schmitz, Corine H. GeurtsvanKessel et al. · 2022 · Clinical Infectious Diseases
50. Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
    Samuel Ponce‐de‐León, Martha Torres, Luis Enrique Soto-Ramírez, Juan José Calva, Patricio Santillán‐Doherty, Dora Eugenia Carranza-Salazar, Juan Manuel Carreño, Claudia Carranza, Esmeralda Juárez, Laura Elena Carreto-Binaghi et al. · 2023 · npj Vaccines
51. Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
    Alexander A. Cohen, Jennifer R. Keeffe, Ariën Schiepers, Sandra Dross, Allison J. Greaney, Annie V. Rorick, Han Gao, Priyanthi N.P. Gnanapragasam, Chengcheng Fan, Anthony P. West et al. · 2024 · Cell
52. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications
    Merav Heshin‐Bekenstein, Amit Ziv, Nataša Toplak, David Hagin, Danielle Kadishevich, Yonatan Butbul, Esther Saiag, Alla Kaufman, Gabi Shefer, Orli Sharon et al. · 2022 · Rheumatology
53. Expert review on global real-world vaccine effectiveness against SARS-CoV-2
    Sunate Chuenkitmongkol, Rontgene Solante, Erlina Burhan, Suwat Chariyalertsak, Nan‐Chang Chiu, Do Van Dung, Masliyana Husin, Kao‐Pin Hwang, Sasisopin Kiertiburanakul, Prasad Suryakant Kulkarni et al. · 2022 · Expert Review of Vaccines
54. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
    Shona C. Moore, Barbara Kronsteiner, Stéphanie Longet, Sandra Adele, Alexandra S. Deeks, Chang Liu, Wanwisa Dejnirattisai, Laura Silva-Reyes, Naomi Meardon, Sian Elizabeth Faustini et al. · 2023 · Med
55. Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade
    Juan Carlos Yam‐Puc, Zhaleh Hosseini, Emily C. Horner, Pehuén Pereyra Gerber, Nonantzin Beristain‐Covarrubias, Robert Hughes, Aleksei Lulla, Maria Rust, Rebecca H. Boston, Magda Mohamed Ali et al. · 2023 · Nature Communications
56. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
    Spyros Chalkias, Charles Harper, Keith W. Vrbicky, Stephen R. Walsh, Brandon J. Essink, Adam B. Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang et al. · 2023 · Nature Communications
57. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge
    Harman Malhi, Leah J. Homad, Yu-Hsin Wan, Bibhav Poudel, Brooke Fiala, Andrew J. Borst, Jing Yang Wang, Carl Walkey, Jason Price, Abigail Wall et al. · 2022 · Cell Reports Medicine
58. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation
    Christian Rolfo, Noy Meshulami, Alessandro Russo, Florian Krammer, Adolfo García‐Sastre, Philip C. Mack, Jorge E Gomez, Nina Bhardwaj, Amin Benyounes, Rafael Sirera et al. · 2021 · Journal of Thoracic Oncology
59. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey
    Derya Çağlayan, Ahmet Furkan Süner, Neslişah Şiyve, Irmak Güzel, Çağlar Irmak, Elif IŞIK, Özgür Appak, Muammer Çelik, Gamze Öztürk, Sema Alp Çavuş et al. · 2022 · Journal of Medical Virology
60. Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
    JERALD C. SADOFF, Mathieu Le Gars, Boerries Brandenburg, Vicky Cárdenas, Georgi Shukarev, Nathalie Vaissière, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Mandy A. C. Jongeneelen et al. · 2021 · Vaccine
61. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
    Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, Shayne F. Andrew, Barbara J. Flynn, Anne P. Werner, Danielle A. Wagner, I‐Ting Teng, Bob C. Lin, Christopher A. Moore et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
62. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
    Venice Servellita, Mary Kate Morris, Alicia Sotomayor-González, Amelia S. Gliwa, Erika Torres, Noah Brazer, Alicia Yiran Zhou, Katherine Hernandez, Madeline Sankaran, Baolin Wang et al. · 2022 · Nature Microbiology
63. A Review on Measures to Rejuvenate Immune System: Natural Mode of Protection Against Coronavirus Infection
    Md. Aminul Islam, Md Atiqul Haque, Md Arifur Rahman, Foysal Hossen, Mahin Reza, Abanti Barua, Abdullah Al Marzan, Tuhin Das, Sumit Kumar Baral, Cheng He et al. · 2022 · Frontiers in Immunology
64. Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
    Chloé Dimeglio, Marion Migueres, Naémie Bouzid, Sabine Chapuy‐Regaud, Caroline Gernigon, Isabelle Da-Silva, Marion Porcheron, Guillaume Martin‐Blondel, Fabrice Hérin, Jacques Izopet · 2022 · Vaccines
65. COVID ‐19 and plasma cells: Is there long‐lived protection?*
    Doan C. Nguyen, Pedro A. Lamothe, Matthew Charles Woodruff, Ankur Singh Saini, Caterina Elisa Faliti, Igñacio Sanz, Frances Eun-Hyung Lee · 2022 · Immunological Reviews
66. Broad-spectrum pan-genus and pan-family virus vaccines
    Chee Wah Tan, Sophie Valkenburg, Leo L. M. Poon, Lin‐Fa Wang · 2023 · Cell Host & Microbe
67. A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates
    Ruth Hunegnaw, Anna N. Honko, Lingshu Wang, Derick Carr, Tamar Murray, Wei Shi, Lam Nguyen, Nadia Storm, Caitlyn N M Dulan, Kathryn E. Foulds et al. · 2022 · Science Translational Medicine
68. Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients
    Santosh Dhakal, Tong Yu, Anna Yin, Nora Pisanic, Zoe O Demko, Annukka A.R. Antar, Andrea L. Cox, Christopher D. Heaney, Yukari Carol Manabe, Sabra L. Klein · 2022 · Open Forum Infectious Diseases
69. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
    David C. Benkeser, David C. Montefiori, Adrian B. McDermott, Youyi Fong, Holly Janes, Weiping Deng, Honghong Zhou, Christopher R. Houchens, Karen A. O. Martins, Lakshmi Jayashankar et al. · 2023 · Science Translational Medicine
70. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
    Dean A. Follmann, Meagan P. O’Brien, Jonathan Fintzi, Michael P. Fay, David C. Montefiori, Allyson Mateja, Gary A. Herman, Andrea T. Hooper, Kenneth C. Turner, K.-C. Chan et al. · 2023 · Nature Communications
71. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
    Jordan J. Clark, Irene Hoxie, Daniel C. Adelsberg, Iden A. Sapse, Robert Andreata‐Santos, Jeremy S. Yong, Fatima Amanat, Johnstone Tcheou, Ariel J. Raskin, Gagandeep Singh et al. · 2024 · Cell Reports
72. Variant-adapted COVID-19 booster vaccines
    Florian Krammer, Ali H. Ellebedy · 2023 · Science
73. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults
    Palmer, Christine D., Scallan, Ciaran D., Kraemer Tardif, Lauren D., Kachura, Melissa A., Rappaport, Amy R., Koralek, Daniel O., Uriel, Alison, Gitlin, Leonid, Klein, Joshua, Davis, Matthew J. et al. · 2023 · Nature Communications
74. Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
    Trung The Tran, Eline Benno Vaage, Adi Mehta, Adity Chopra, Lisa Tietze, Anette Kolderup, Aina Karen Anthi, Marton Skog Steinberger König, Gro Owren Nygaard, Andreas Lind et al. · 2022 · npj Vaccines
75. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
    David C. Benkeser, Youyi Fong, Holly Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule, Ann Marie Stanley, Jill Maaske, Tonya L. Villafana, Christopher R. Houchens et al. · 2023 · npj Vaccines
76. COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective
    Jasmine Riviere Marcelin, Audrey E. Pettifor, Holly Janes, Elizabeth R. Brown, James G. Kublin, Kathryn E. Stephenson · 2022 · Open Forum Infectious Diseases
77. Seroconversion and outcomes after initial and booster COVID ‐19 vaccination in adults with hematologic malignancies
    Thomas A. Ollila, Rebecca H. Masel, John Leonard Reagan, Shaolei Lu, Ralph Rogers, Kimberly J. Paiva, Rashida Taher, Ella Burguera‐Couce, Adam S. Zayac, Inna Yakirevich et al. · 2022 · Cancer
78. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn
    Flor M. Muñoz, Christine M. Posavad, Barbra A. Richardson, Martina L. Badell, Katherine E. Bunge, Mark J. Mulligan, Lalitha Parameswaran, Clifton W. Kelly, Courtney Olson‐Chen, Richard M. Novak et al. · 2023 · Vaccine
79. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study
    Houda Amellal, Najlaa Assaid, Hicham Charoute, Khadija Akarid, Abderrahmane Maaroufi, Sayeh Ezzikouri, M’hammed Sarih · 2023 · PLoS ONE
80. Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
    Billy J. Gardner, Auston Marm Kilpatrick · 2024 · Viruses
81. Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children
    Youjia Zhong, Alicia Yi Hui Kang, Carina Jing Xuan Tay, Hui’ En Li, Nurul Elyana, Chee Wah Tan, Wee Chee Yap, Joey Ming Er Lim, Nina Le Bert, Kuan Rong Chan et al. · 2024 · Nature Medicine
82. SARS-CoV-2 correlates of protection from infection against variants of concern
    Kaiyuan Sun, Jinal N. Bhiman, Stefano Tempia, Jackie Kleynhans, Vimbai Sharon Madzorera, Qiniso Mkhize, Haajira Kaldine, Meredith McMorrow, Nicole Wolter, Jocelyn Moyes et al. · 2024 · Nature Medicine
83. Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
    John E. Bowen, Kaitlin R. Sprouse, Alexandra C. Walls, Ignacio G. Mazzitelli, Jennifer K. Logue, Nicholas Franko, Kumail Ahmed, Asefa Shariq Ansari, Elisabetta Cameroni, Andrea Gori et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
84. Decreased memory B cell frequencies in COVID‐19 delta variant vaccine breakthrough infection
    Matthew Zirui Tay, Angéline Rouers, Siew‐Wai Fong, Yun Shan Goh, Yi‐Hao Chan, Zi Wei Chang, Weili Xu, Chee Wah Tan, Wan Ni Chia, Anthony Torres‐Ruesta et al. · 2022 · EMBO Molecular Medicine
85. Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19
    Mihaela Chivu‐Economescu, Coralia Bleoţu, Camelia Grancea, Daniela Chiriac, Anca Botezatu, Iulia Virginia Iancu, Ioana Mădălina Pitica, Laura Georgiana Necula, Ana Iulia Neagu, Lilia Matei et al. · 2022 · Journal of Cellular and Molecular Medicine
86. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
    Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan Fan‐Ngai Hung, Wai‐Kay Seto, Man‐Fung Yuen · 2022 · Clinical and Molecular Hepatology
87. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
    Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, Corine H. GeurtsvanKessel, Yvonne M. Mueller, Virgil A. S. H. Dalm, Grigorios Papageorgiou, Hanka Steggink, Alicja Górska, Susanne Bogers et al. · 2022 · PLoS Medicine
88. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
    Timothy J.C. Tan, Zongjun Mou, Ruipeng Lei, Wenhao O. Ouyang, Meng Yuan, Ge Song, Raiees Andrabi, Ian A. Wilson, Collin Kieffer, Xinghong Dai et al. · 2023 · Nature Communications
89. Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion
    Tabea M. Eser, Olga Baranov, Manuel Huth, Mohammed I. M. Ahmed, Flora Deák, Kathrin Held, Luming Lin, Kami Pekayvaz, Alexander Leunig, Leo Nicolai et al. · 2023 · Nature Communications
90. Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
    Anisha Misra, Elitza S. Theel · 2022 · Journal of Clinical Microbiology
91. Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of Antibody Titers
    Katharina Willuweit, Alexandra Frey, Moritz Passenberg, Johannes Korth, Nissrin Saka, Olympia Evdoxia Anastasiou, Birte Möhlendick, Andreas Schütte, Hartmut Schmidt, Jassin Rashidi‐Alavijeh · 2022 · Vaccines
92. COVID-19 vaccines: Immune correlates and clinical outcomes
    Shant H. Mahrokhian, Lisa H. Tostanoski, Samuel J. Vidal, Dan H. Barouch · 2024 · Human Vaccines & Immunotherapeutics
93. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
    Alfredo J Mena Lora, Jessica E. Long, Yunda Huang, Lindsey Robert Baden, Hana M. El Sahly, Dean A. Follmann, Paul Goepfert, Glenda Gray, Beatriz Gilda Jegerhorn Grinsztejn, Karen L. Kotloff et al. · 2023 · JAMA Network Open
94. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies
    Nathan J. Cheetham, Milla Kibble, Andrew Wong, Richard J. Silverwood, Anika Knüppel, Dylan M. Williams, Olivia KL Hamilton, Paul Hong Lee, Charis Bridger Staatz, Giorgio Di Gessa et al. · 2023 · eLife
95. Covid-19 vaccination: evidence of waning immunity is overstated
    Jake A. Scott, Aaron G. Richterman, Müge Çevik · 2021 · BMJ
96. Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
    Tomer Hertz, Shlomia Levy, Daniel A. Ostrovsky, Hanna Oppenheimer, Shosh Zismanov, Alona Kuzmina, Lilach M. Friedman, Sanja Trifkovic, David C. Brice, Lin Chun-Yang et al. · 2023 · Nature Communications
97. Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic
    Oliver D. Eales, Michael John Plank, Benjamin John Cowling, Benjamin P. Howden, Adam J. Kucharski, Sheena G. Sullivan, Katelijn Vandemaele, Cecile G. Viboud, Steven Riley, James M. McCaw et al. · 2024 · Emerging infectious diseases
98. Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial
    Spyros Chalkias, Patrick Dennis, Dena Petersen, Krishnakumar Radhakrishnan, Leroy B. Vaughan, Reem Handforth, Alexandra Rossi, Rahnuma Wahid, Darin K. Edwards, Jing Feng et al. · 2025 · The Lancet Infectious Diseases
99. The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination
    Robert J. Benschop, JAY L. TUTTLE, Lin Zhang, Josh Poorbaugh, Nicole L. Kallewaard, Peter Vaillancourt, Melissa Crisp, Thi Ngoc Vy Trinh, Joshua J. Freitas, Stephanie Beasley et al. · 2022 · Science Translational Medicine
100. Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2
     Ariana Ghez Farrell, Bernadeta Dadonaite, Allison J. Greaney, Rachel T. Eguia, Andrea N. Loes, Nicholas Franko, Jennifer K. Logue, Juan Manuel Carreño, Anass Abbad, Helen Y. Chu et al. · 2022 · Viruses